• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Weekly Roundup: February 8-12, 2021


In case you missed it, some of this week’s featured content includes the latest FDA approvals, newly published phase 3 data for tirbanibulin, oxytocin and its effect on skin aging, plus more.

POLL: Do you know how to recognize blastic plasmacytoid dendritic cell neoplasm (BPDCN)?

The Mainstream Patient: February 8, 2021

This week’s edition of The Mainstream Patient features stories on tretinoin, dermal fillers, dermarolling, niacinamide, and more.

New AAD-NPF Psoriasis Guidelines Mark Changes

New AAD-NPF guidelines focus on biologics, topical therapy, systemic non-biological therapies, management of pediatric patients, use of phototherapy and comorbidities.

New Year, New drugs for Psoriasis

According to one expert, recently completed phase 3 trials of novel drugs have shown impressive results, with 2021 expected to be an exciting year that will bring further advances in treatment options for patients with moderate-to-severe plaque psoriasis.

FDA Approves Cemiplimab for Advanced Basal Cell Carcinoma

The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.

Can Early Exposure to Farm Animals Reduce AD Risk? ­

Spending time around animals as an infant has been suggested as a way to reduce the incidence of atopic dermatitis. An investigation offers some insight.

Topical Probiotics Perform Well in Trials

Topical probiotics show promise in treating various skin diseases including acne, but more research is needed.

Tirbanibulin Safe, Effective for AK on Face, Scalp

Topical microtubule inhibitor, tirbanibulin (Klisyri, Almirall), demonstrates positive results for treating actinic keratosis (AK) of the face and scalp, according recently published data from two phase 3 studies.

Oxytocin and its Effect on Skin Aging

Nicole Hayre, MD, FAAD, discusses her recent research related to oxytocin's effect on skin aging and how increased levels of oxytocin in the body can make the skin appear younger.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.